BiotechTube

Lu AG06466 + Placebo

Phase 1Completed
0 watching 0 views this week💤 Quiet
30
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

PTSD

Conditions

PTSD

Trial Timeline

Sep 30, 2020 → Feb 13, 2023

NCT ID
NCT04597450

About Lu AG06466 + Placebo

Lu AG06466 + Placebo is a phase 1 stage product being developed by Lundbeck for PTSD. The current trial status is completed. This product is registered under clinical trial identifier NCT04597450. Target conditions include PTSD.

Hype Score Breakdown

Clinical
10
Activity
5
Company
7
Novelty
3
Community
2

Clinical Trials (5)

NCT IDPhaseStatus
NCT05177029Phase 1Terminated
NCT05081518Phase 1Terminated
NCT04990219Phase 1Terminated
NCT04974359Phase 1Terminated
NCT04597450Phase 1Completed

Competing Products

11 competing products in PTSD

See all competitors
ProductCompanyStageHype Score
SYN117 (nepicastat) + Placebo comparatorJohnson & JohnsonPhase 2
52
Quetiapine + PlaceboJohnson & JohnsonApproved
85
Mifepristone 1200 mg daily + PlaceboCorcept TherapeuticsPhase 2
47
TNX-102 SLTonix PharmaceuticalsPhase 2
44
TNX-102 SL 5.6 mgTonix PharmaceuticalsPhase 3
69
TNX-102 SL + PlaceboTonix PharmaceuticalsPhase 2
44
TNX-102 SL + Placebo SL TabletTonix PharmaceuticalsPhase 3
69
TNX-102 SL + PlaceboTonix PharmaceuticalsPhase 2
44
TNX-102 SL + Placebo SL TabletsTonix PharmaceuticalsPhase 3
69
TNX-102 SLTonix PharmaceuticalsPhase 3
69
Ganaxolone + PlaceboBrain BiotechPhase 2
44

Other Products from Lundbeck

VortioxetineApproved
82
memantine + memantine + placeboApproved
82
escitalopram + escitalopramApproved
82
BrexpiprazoleApproved
82
losartan (drug)Approved
82